The Uromigos

Episode 54: Biomarkers in prostate cancer with Chris Sweeney 24.07.2020 25:05 ↓

Some thought it would never come - the final podcast of the World Tour from Boston.

Episode 53: Still in Boston - biomarkers in bladder cancer 24.07.2020 18:43 ↓

Tom, Brian and Chris Sweeney discuss the challenges of development of biomarkers for immune therapy in bladder cancer. 

Episode 52: The Final Stop - Boston: David McDermott discusses biomarkers in renal cancer in the era of immune therapy 24.07.2020 20:01 ↓

Tom, David and Brian discuss biomarkers in renal cancer in the era of immune therapy.

Episode 51: The Uromigos World Tour is in Norway with Jan Oldenburg - discussing key topics in testis cancer 18.07.2020 22:52 ↓

Jan Oldenburg from Norway discusses treatment choices for stage 1 testis cancer, the dilemma of high dose therapy for relapse and long term toxicity of chemotherapy. 

Episode 50: The Uromigos World Tour in London with renal cancer surgery 15.07.2020 22:53 ↓

Axel Bex talks about small renal masses, robotic vs partial nephrectomy and surgery in metastatic disease. 

Episode 49: The Tour remains in Germany with Oliver Grimm and renal cancer 14.07.2020 22:15 ↓

The World Tour stays in Germany to discuss the first line renal cancer (clear cell and non-clear cell) and clinical trials with Oliver Grimm. 

Episode 48: ...and then Germany - Jürgen Gschwend discusses cystectomy for urothelial cancer 10.07.2020 20:38 ↓

Jürgen discusses German research and surgery for bladder cancer. The podcast ends abruptly - which was not his fault! 

Episode 46: The Uromigos World Tour in Spain discussing SOGUG and Renal Cancer with Cristina Suarez 09.07.2020 19:38 ↓

Cristina Suarez discusses the success of clinical trials in Spain, and access to treatments. 

Episode 45: The Uromigos World Tour arrives in Japan 03.07.2020 20:29 ↓

Yoshi Tomita explains treatment pathways and research in GU cancer in Japan. Brian explains why he likes Japan so much. 

Episode 44: The Uromigos World Tour in Australia - Talking with Ian Davis about prostate cancer and ANZUP 03.07.2020 31:51 ↓

Ian Davis discusses why ANZUP has been so successful, and the EnzaMet study. An uninvited guest arrives towards the end. 

Episode 43: The Uromigos World Tour in Singapore with Ravi Kanesvaran 29.06.2020 18:20 ↓

Ravi describes treatment pathways and research for Southeast Asia in GU cancer. 

Episode 42: The Uromigos in Argentina 28.06.2020 12:08 ↓

Juan Sade discusses research, treatment pathways in GU cancer, steak and red wine in Argentina. 

Episode 41: The Uromigos World Tour lands in Brazil - Fernando Maluf talks about prostate cancer and recent research in Brazil 25.06.2020 24:04 ↓

The tour lands in sunny Brazil with a trip to a Japanese restaurant and a discussion about research and prostate cancer. 

Episode 40: The Uromigos World Tour moves to France - Bernard Escudier discusses 2nd line therapy in renal cancer and Tivozanib 22.06.2020 20:02 ↓

The Uromigos World Tour moves to Paris. Treatment for tumours that progress after first line immunetherapy is discussed. The role of Tivozanib is a focus for the dialogue. 

Episode 39: The Uromigos World Tour - Renal Cancer and IMDC Risk with Danny Heng in Calgary 18.06.2020 20:17 ↓

Danny discusses Italian food and the past, present and future of the IMDC prognostic score. 

Episode 38: The Uromigos Virtual World Tour - starting in Vancouver with Atezolizumab in NMIBC 16.06.2020 20:21 ↓

Peter Black talks about his recent BCG refractory NMIBC ASCO presentation and its implications for the field. 

Episode 37: Regoratinib (FGFR inhibitor) and Atezolizumab in UC with Jonathan Rosenberg 01.06.2020 18:11 ↓

Everything you wanted to know about FGFR inhibition but were afraid to ask. 

Episode 36: Dr. Tian Zhang discusses three ASCO bladder cancer abstracts with immune therapy/targeted therapy combinations 01.06.2020 20:58 ↓

 Tian Zhang discusses three ASCO bladder cancer abstracts with immune therapy/targeted therapy combinations

Episode 35: Maintenance Avelumab in Bladder Cancer (LBA1) 31.05.2020 17:41 ↓

Dr. Kala Sridhar, Professor Tom Powles and Dr. Brian Rini discuss the data presented at ASCO. 

Episode 34: Savolitinib in Renal Papillary Cancer - A Major Breakthrough? 30.05.2020 20:40 ↓

Dr. Toni Choueiri discusses the results of this study, which appears to show a survival signal, but it is difficult to interpret. 

Episode 33: Adjuvant Atezolizumab in Urothelial Cancer 29.05.2020 19:59 ↓

Joaquim Bellmunt explains a bit about why this trial was not successful and what it means for the field. 

Episode 32: A Phase 2 Study of PSMA PET in Prostate Cancer with Thomas Hope from ASCO 2020 29.05.2020 24:09 ↓

Thomas Hope is quizzed on the results of his study presented at ASCO20.

Episode 31: A Phase 2 Study of Nivolumab with the Addition of Ipilimumab Upon Progression in Renal Cancer 29.05.2020 25:18 ↓

Mike Atkins describes the results of this study which helps shed light on the role of ipilimumab and nivolumab in this disease. 

Episode 30: Update on Axitinib plus Pembrolizumab in Renal Cancer (KEYNOTE 426) 29.05.2020 20:03 ↓

Betsy Plimack discusses the updated data with a minimum of 23 months' follow up. Dr. Brian Rini and Professor Tom Powles asks what it adds. 

Episode 29: PSMA PET at ASCO 2020 with Mike Morris 29.05.2020 23:47 ↓

Mike Morris presents the findings in his prospective study.